H2020Докторантска мрежа2018–2022

COSMIC · COmbatting disorders of adaptive immunity with Systems MedICine

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2018-01-01 → 2022-09-30
Финансиране от ЕС
3 605 245 €
Участници
18
Схема
MSCA-ITN

Линиите свързват координатора с партньорите.

Накратко на български

Работата на герминалните центрове в имунната система се анализира при заболявания като ревматоиден артрит и B-клетъчни неоплазии. Разбирането на тези механизми помага за по-точна диагноза и подобряване на управлението на пациентите с хронични заболявания.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

COmbatting disorders of adaptive immunity with Systems MedICine

Combatting B-cell neoplasia and rheumatoid arthritis with systems medicine EU countries face large health challenges to combat chronic diseases. COSMIC pursued a Systems medicine approach comprising the integration of laboratory and computational approaches to combat B-cell neoplasia (BCN) and rheumatoid arthritis (RA) both prototypical diseases originating from abnormal functioning of immune cells. These immune-related diseases pose a variety of challenges including (1) an incomplete understanding of the underlying molecular/cellular mechanisms, (2) uncertain diagnosis/prognosis and (3) variable treatment efficacies of existing drugs. This results in suboptimal patient management and huge costs for healthcare systems. In particular, COSMIC focussed on the incorrect functioning of the germinal center (GC) which contributes to the emergence of B-cell clones expressing autoreactive antibodies in RA, or showing a malignant behaviour in BCN. GCs are specialised anatomical sites for example found in lymph nodes and make part of the adaptive immune system. To determine the role of the GC in RA and BCN is challenging as it is not easily accessible for experimental investigation. Therefore, we developed new experimental approaches and computational models to gain more insight in the (patho)physiological cellular and molecular mechanisms underlying the (dis)function of the GC. This will contribute to the elucidation of the the GC reaction and is essential to understand the ontogeny and evolution of BCN and RA.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Background: EU countries face large health challenges to combat chronic diseases. Recently, systems medicine has emerged as a promising discipline to accelerate the translation of basic research into applications for improved diagnostics and personalized treatment. Its power arises from the integration of laboratory and computational approaches crossing research disciplines and sectors to solve clinical questions. COSMIC delivers the next generation of leading, entrepreneurial, and innovative systems medicine professionals having expertise, skills, and experience to successfully combat complex human disorders. These professional will find excellent career opportunities. COSMIC focuses on B-cell neoplasia and rheumatoid arthritis, prototypical diseases originating from abnormal functioning of immune cells, often resulting in similar antigen specificities. COSMIC enables Early Stage Researchers to play a leading role in this exciting field.Approach: COSMIC develops and integrate experimental and computational approaches and establish a unique cross-fertilization between oncology and auto-immunity. In addition to transferable skills, the training program focuses on establishing a double expertise in laboratory and computational to address clinical questions. It involves a wide-range of stakeholders: (pre)clinical departments, companies, patient groups, students, and the general public. COSMIC will establish a link with the leading European EASyM and ISBE initiatives, and aims to harmonize systems medicine training throughout Europe by connecting to other EU (Marie Curie systems medicine) training initiatives.Impact: COSMIC (i) significantly improves ESR career perspectives (ii) leads to new public-private collaborations increasing competitiveness for companies; (iii) contributes to future oncology and immunology medical care; (iv) contributes to the EU systems medicine best practices.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз